ClinicalTrials.gg
CompletedNCT05016193Updated Aug 13, 2024

Independent Use of Brain Measurement-Based Rehabilitation System by Stroke Survivors

An interventional study of Axem Home Prototype Device and Rehabilitation Exercise Program in Stroke, sponsored by University of Calgary. Completed at 1 site in Canada. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by University of Calgary · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The Axem Home study is a randomized open label trial analyzing the safety and feasibility of coupling the Axem Home prototype device with exercise to improve motor recovery following a stroke.

Read the detailed description

The Axem Home study is a randomized, open label, phase I clinical trial evaluating the safety and feasibility of coupling feedback to participants on their levels of sensorimotor brain activity (via the Axem Home prototype device) with exercise rehabilitation. 15 participants will be enrolled in each arm of the study. Both groups will participate in an exercise program, but only one group (the intervention group) will receive the Axem Home prototype device.

Study participants will be evaluated at baseline, after 3 weeks, and after 6 weeks (upon the completion of their time in the Early Supported Discharge program). Evaluators will be blinded as to which group participants are in. The study is constructed with randomization to remove selection and allocation biases.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Rehabilitation
  • Neurofeedback
  • Functional near-infrared spectroscopy
  • Neuroergonomics
  • Motor cortex
  • Gamification
03

In context

Stroke

7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.

This study's enrollment of 30 is below the median of 50 across 5,482 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

University of Calgary is the lead sponsor of 699 studies on the registry; 192 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 2 (20%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Accepted into the Calgary Stroke Program's Early Supported Discharge program for stroke survivors
  • Aged 18 or older
  • Visual acuity better than 20/50 in both eyes
  • Able to give consent
  • Clinician reported upper-extremity movement deficit

Exclusion Criteria:

  • Score ≥15 on the PHQ-9
  • Score \<10 on the MoCA or \<20 on the CASP
  • Inclusion in another interventional trial
  • Have open wounds on their scalp
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Intervention Group

    * Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist. * Participants will be asked to wear the Axem Home prototype headband when doing their daily upper-extremity rehabilitation exercises at home. * Participants will perform a short motor assessment while wearing the Axem Home prototype headband once per week.

    Device: Axem Home Prototype Device · Behavioral: Rehabilitation Exercise Program

  • Active comparator
    Control Group

    * Participants will attend 3 assessment sessions: one at the beginning of the study, one after about 3 weeks, and one at the end of the study. These sessions will be conducted by a trained physiotherapist. * Participants will be asked to keep track of how many minutes of rehabilitation they have completed as per standard care. * Participants will perform a short motor assessment while wearing the Axem Home prototype headband once at the beginning of the study and again at the end of the study during the clinical assessment sessions.

    Behavioral: Rehabilitation Exercise Program

Interventions

  • DeviceAxem Home Prototype Device

    The Axem Home prototype device is a rehabilitation system designed to be used independently by a stroke survivor to facilitate physical rehabilitation exercises in their home environment. The device uses a functional near-infrared spectroscopy (fNIRS) headband that measures the hemodynamic response to rehabilitation exercises and displays this brain activity information to the user.

  • BehavioralRehabilitation Exercise Program

    Individual exercise program prescribed by a therapist in the Early Supported Discharge Program.

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events Related to the Axem Home Prototype Device (Safety and Tolerability)

    The ability of participants in the intervention group to complete the study using the Axem Home prototype device without experiencing an adverse event.

    Time frame: Intervention group only: through study completion, an average of 6 weeks

  2. Usability Interview

    A short, semi-structured interview asking participants in the intervention group for qualitative assessments of various aspects of the Axem Home prototype device software and headband, in order to ascertain any potential areas where either might need to be improved.

    Time frame: Intervention group only: once per week for an average of 6 weeks and post-intervention (after study completion, an average of week 6)

  3. Usability Questionnaire

    A short questionnaire asking participants in the intervention group to rate various aspects of the Axem Home prototype device with respect to its usability and perceived usefulness.

    Time frame: Intervention group only: post-intervention (after study completion, an average of week 6)

  4. Participation

    The number of participants in the intervention group that choose to discontinue participation in the study without experiencing an adverse event.

    Time frame: Intervention group only: through study completion, an average of 6 weeks

Secondary outcomes

  1. Change in Fugl-Meyer Assessment (FMA) of Motor Recovery

    A stroke-specific, performance-based impairment index. The FMA is designed to assess motor functioning, sensation, balance, joint range of motion and joint pain in patients with post-stroke hemiplegia. Sub-scales include: upper extremity (0-36), wrist (0-10), hand (0-14), coordination/speed (0-6) (which can be combined to form a total motor function score out of 66), and sensation (0-4). Higher scores indicate better performance.

    Time frame: Baseline, week 3, and post-intervention (after study completion, an average of week 6)

  2. Change in Action Research Arm Test (ARAT) score

    The ARAT assesses arm function to determine the quality of the arm movement, and the limitation of activity. The ARAT consists of 4 sub-tests; that examines and individual's grip, grasp, pinch and gross motor movement in order to determine upper extremity function. Objects of varying size, shape, and weight must be either grasped, handled or moved in a specific task in order to evaluate function. Low scores mean worse function with the minimum possible score being 0 and the highest possible score being 57 (normal function).

    Time frame: Baseline, week 3, and post-intervention (after study completion, an average of week 6)

  3. Stroke Impact Scale (SIS)

    Stroke-specific, self-report, health status measure. Assesses multiple domains on a 5-point Likert scale. Domains include: strength (4-20), hand function (5-25), activities of daily living/instrumental activities of daily living (10-50), mobility (9-45), communication (7-35), emotion (9-45), memory and thinking (7-35), and participation (8-40). An extra question asks that the patient rate on a scale from 0 - 100 how much they feel that he/she has recovered from his/her stroke. The 4 physical domains (strength, hand function, mobility and activities of daily living) can be summed together to create a single, physical dimension score (28-140) while all other domains should remain separate. Higher scores indicate better function.

    Time frame: Baseline, week 3, and post-intervention (after study completion, an average of week 6)

  4. National Institutes of Health Stroke Scale (NIHSS)

    A 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. Higher scores indicate greater impairment.

    Time frame: Baseline

  5. Cognitive Assessment for Stroke Patients (CASP)

    A questionnaire designed to measure cognitive function in patients regardless of the presence of aphasia, with lower scores indicating greater impairment.

    Time frame: Baseline

  6. Patient Health Questionnaire (PHQ-9)

    A major depressive disorder sub-scale of the full PHQ; used to provisionally grade depressive symptoms in patients. Higher scores indicate the presence of more severe depression.

    Time frame: Baseline

  7. Montreal Cognitive Assessment (MoCA)

    A cognitive screening test used to assess: short term memory, visuospatial abilities, executive functions, attention, concentration, working memory, language, and orientation to time and place. Higher scores indicate better function.

    Time frame: Baseline

  8. Snellen Eye Chart Assessment of Visual Acuity

    Vision will be screened at study entry using a Snellen Eye chart, with acuity ranging from 20/20 (higher acuity) to 20/200 (lower acuity).

    Time frame: Baseline

  9. Clinician Assessment of Vision

    Vision will be screened at study entry by clinician observation to assess visual fields for the presence of visual neglect.

    Time frame: Baseline

  10. Functional Independence Measure (FIM)

    The FIM rates subjects on 18 items across many functions such as eating, grooming, bathing and dressing on a scale from 1 (total assistance needed) to 7 (complete independence). Lowest possible score is 18 (lowest independence) and the best possible score is 126 (completely independent). The FIM is the standard measure used by rehabilitation facilities in Canada and the United States to evaluate overall function and burden of care.

    Time frame: Baseline and post-intervention (after study completion, an average of week 6)

  11. Modified Rankin Scale (mRS)

    A disability rating scale from 0 (no symptoms at all) to 6 (deceased).

    Time frame: Baseline and post-intervention (after study completion, an average of week 6)

  12. Thumb Localizing Test

    A standardized assessment of proprioception. Scores range from 1 (no difficulty) to 3 (severe difficulty), with lower scores indicating better function.

    Time frame: Baseline and post-intervention (after study completion, an average of week 6)

  13. Strength

    Strength will be assessed using the Medical Research Council scale for muscles in the upper extremity. Scores range from 0 (no movement observed) to 5 (muscle contracts normally against full resistance).

    Time frame: Baseline and post-intervention (after study completion, an average of week 6)

  14. Modified Ashworth Scale (MAS)

    A strength scale used to assess muscle tone during flexion and extension. Scores range from 0 (no increase in tone) to 4 (affected part(s) rigid in flexion or extension), with lower scores indicating better function.

    Time frame: Baseline and post-intervention (after study completion, an average of week 6)

  15. Functional Near-Infrared Spectroscopy (fNIRS) Measures

    Brain activity feedback from the motor cortex measured during rehabilitation exercises.

    Time frame: Intervention group: baseline, once per week for an average of 6 weeks, and post-intervention (after study completion, an average of week 6). Control group: baseline and post-intervention (after study completion, an average of week 6)

  16. Recording of Assigned Home Exercises

    Recording of the specific homework exercises assigned by the therapist that the participant completes throughout the week.

    Time frame: Weekly (for an average of 6 weeks)

  17. Home Exercise Compliance

    Proportion of a given participant's weekly assigned home exercise volume (in minutes) they complete.

    Time frame: Weekly (for an average of 6 weeks)

  18. Video Capture

    This data will be used to confirm that the Axem Home prototype device has been correctly placed and securely fitted on the head, which is an assumption of the analysis of functional near-infrared spectroscopy (fNIRS) measures.

    Time frame: Intervention group only: rehabilitation sessions (for an average of 6 weeks)

  19. Magnetic Resonance Imaging (MRI)

    Structural images taken from within the first week after stroke (if available). These images will be used to document lesion location and size, and to provide underlying information about functional connections between brain structures.

    Time frame: Images taken from within the first week after stroke; collected during the baseline assessment

  20. Computed Tomography Scan Imaging (CT)

    Structural images taken from within the first week after stroke (if available). These images will be used to document lesion location and size, and to provide underlying information about functional connections between brain structures.

    Time frame: Images taken from within the first week after stroke; collected during the baseline assessment

07

Study locations

1 site
  • Calgary Stroke Program Early Supported Discharge
    Calgary, Alberta T2N 4N1, Canada
08

References and documents

Publications

  • Mihara M, Hattori N, Hatakenaka M, Yagura H, Kawano T, Hino T, Miyai I. Near-infrared spectroscopy-mediated neurofeedback enhances efficacy of motor imagery-based training in poststroke victims: a pilot study. Stroke. 2013 Apr;44(4):1091-8. doi: 10.1161/STROKEAHA.111.674507. Epub 2013 Feb 12. PubMed 23404723 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05016193
Collaborators
Axem Neurotechnology Inc.
Responsible party
Sponsor
First posted
Aug 23, 2021
Start date
Aug 1, 2021
Primary completion
Aug 1, 2024
Completion
Aug 9, 2024
Last update
Aug 13, 2024

Study contacts

Sean Dukelow, MD PhD FRCPC
principal investigator · University of Calgary

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion